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Objectives This study sought to estimate the costs of a national electrocardiographic (ECG) screening of athletes in the
United States and the number of lives that would be saved by that program.
Background A single study from Italy suggests that mandatory ECG screening of athletes reduces their risk of sudden cardiac
death. Based on that study, ECG screening of athletes is endorsed by the European Society of Cardiology, though
not by the American Heart Association. The widespread application of ECG screening remains controversial be-
cause the absolute reduction of sudden cardiac death risk provided, and its economic ramifications, have not
been studied in detail.
Methods A cost-projection model was based on the Italian study, replicating its data in terms of athlete characteristics
and physician performance. The size of the screening-eligible population was estimated from data provided by
the National Collegiate Athletic Association and the National Federation of State High School Associations. The
costs of diagnostic tests were obtained from Medicare reimbursement rates.
Results A 20-year program of ECG screening of young competitive athletes in the United States would cost between $51
and $69 billion and could be expected to save 4,813 lives. Accordingly, the cost per life saved is likely to range
between $10.6 and $14.4 million.
Conclusions Our cost-projection model suggests that replicating the Italian strategy of ECG screening in the United States
would result in enormous costs per life saved. (J Am Coll Cardiol 2012;60:2271–6) © 2012 by the American
College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.09.003Prevention of sudden cardiac death (SCD) among athletes
is a universal goal, though the optimal strategy for its
achievement is controversial (1–4). Specifically, mandatory
electrocardiographic (ECG) screening of all competitive
athletes is recommended by the European Society of Car-
diology (ESC) (5), but not by the American Heart Associ-
ation (6).
The ESC recommendations (5) are based primarily on a
single Italian study (7) that suggests that ECG-based
screening of athletes is beneficial. That study by Corrado et
al. (7) reported a marked decline in the incidence of SCD
among athletes following the implementation of an Italian
law mandating ECG screening, amounting to a 79% relative
risk reduction. However, the absolute risk reduction
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accepted September 4, 2012.achieved through mandatory ECG screening in Italy, the
cost of such a program, and its economic ramifications, were
never studied in detail nor were they addressed in the ESC
guidelines. Knowing the cost of the screening process, and
the actual cost per life saved, allows for prioritization of
protective strategies at the national level (8). Therefore, we
See page 2277
created the present model to: 1) estimate the number of
athletes that would need to undergo screening if mandatory
screening was to be enforced in the United States; 2)
compute the cost of this strategy; and 3) determine the
number of lives that would conceivably be saved.
Methods
We used a cost-projection model to estimate the national
annual expenditure related to mandatory ECG screening of
competitive young athletes in the United States as well as
the cost of saving a single athlete’s life. The model repro-
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reported by Corrado et al. (7), in
terms of patient characteristics
and physicians’ performance.
That study (7) demonstrated a
statistically significant associa-
tion between the onset of man-
datory ECG screening of ath-
letes in Italy and a reduction in
their annual incidence of sudden
death. Importantly, the survival
benefit attributed to mandatory
ECG screening became gradually
evident over the course of 20
years of repeated annual screening (Fig. 1A) (7). Accord-
ingly, the period of mandatory screening used in our model
was 20 years (Fig. 1B).
The cost-projection model was structured on assump-
tions derived from the Corrado data (7) and were based on
U.S. data concerning athletic activity and healthcare costs.
First, we estimated the number of young athletes that would
require ECG screening over 2 decades. Then, we calculated
the type, number, and costs of tests that would be performed
in this population, including secondary testing driven by
abnormal ECG findings. Lastly, by extrapolating the Italian
data (7), we estimated the number of lives saved by ECG
screening.
Number of athletes to be screened over 2 decades. In
keeping with the inclusion criteria of the Italian study (7),
young athletes in the United States were defined as regis-
tered participants in organized high school, college, and
professional sporting activities. Data pertaining to partici-
pation in competitive high school and intercollegiate sports,
and the annual rates of new enrollment in these activities
over the last decade, were obtained from the National
Collegiate Athletic Association Membership Report (9) and
the National Federation of State High School Associations
Participation Data Report (10). Based on these data (Online
Table 1), the mean annual increment in the number of
young athletes over the last decade was 1.53% per year for
high school athletes and 1.81% per year for college athletes.
Assuming that the annual growth in the number of young
athletes remains constant, we estimated that by 2013 (the
arbitrary onset of the 2-decade screening period), the
number of registered competitive athletes would be
8,568,369 (Online Table 1). We ignored the professional
athletes population because 2% of college athletes ulti-
mately join professional sporting leagues (11). For simplic-
ity, the athlete population requiring screening at initiation
of the program was rounded to 8,500,000. Thereafter, the
number of new athletes (1.53% to 1.81% per year) would
compensate for the 2% per year disqualification rate from
sport activity that, based on data from Italy, is expected to
result from ECG screening. Accordingly, in our model, 8.5








ESC  European Society of
Cardiology
MRI  magnetic resonance
imaging
SCD  sudden cardiac
deathnext 2 decades, 170,000 athletes (2%) are disqualified fromsport participation every year, and the number of athletes
requiring screening during subsequent years remains con-
stant. Overall, 2 decades of screening results in 170 million
screening processes and 3.4 million (2%) disqualifications.
Number and type of tests to be performed. Diagnostic-
testing rates in the model reflect the findings of Corrado et
al. (7). In accordance with Italian law, from 1982 to 2004,
all Italian athletes underwent medical screening consisting
of: 1) medical history (focusing on syncope, palpitations,
exertion-related symptoms, and family history of SCD); 2)
physical examination; and 3) resting ECG. These tests were
repeated annually. Abnormal findings during basic screen-
ing led to further diagnostic tests. The number and type of
“secondary” tests was retrieved from a subanalysis of 42,386
athletes who underwent screening in Padua, Italy, between
1982 (the year when mandatory screening started) and 2004
(the end of data collection by Corrado et al. [7]). Of these,
91% had normal ECG, whereas 9% had ECG abnormalities
that drove further testing. The last group consisted of 7% of
Figure 1 Reduction of Annual Incidence and
Predicted Survival of SCD
(A) Reduction of the annual incidence of sudden cardiac death (SCD) among
athletes associated with mandatory electrocardiographic screening in Italy (7).
The law mandating electrocardiographic (ECG) screening of athletes was imple-
mented in 1982. Comparison of the annual incidence rate of SCD in athletes
in a pre-screening period lasting 3 years (1979 to 1981) to the rate after 2
decades of annual screening yielded a 79% relative risk reduction. (B) Pre-
dicted survival curves with and without screening of young athletes in the
United States. The red line denotes the expected annual SCD rate among the
unscreened athlete population, which remains constant at 4 per 100,000 ath-
letes. The blue line denotes the expected annual SCD rate among the popula-
tion of athletes undergoing ECG screening. The annual mortality rate decreases
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athletes eventually disqualified because of abnormal second-
ary tests (7). The type and number of secondary tests
performed appear in Online Table 2. Overall, 9.2%, 3.1%,
nd 1.2% underwent echocardiography, exercise testing, and
olter monitoring, respectively. Additionally, 0.2% of ath-
etes underwent 1 or more of the following: cardiac mag-
etic resonance imaging (MRI); cardiac catheterization;
nd/or electrophysiologic studies (EPS). Because the parti-
ion of these 3 tests was not specified, we averaged their
osts (MRI, catheterization, and EPS) and assumed that
.2% of screened athletes would undergo a single test of that
ost. This assumption is conservative considering, for ex-
mple, that patients with suspected right ventricular dyspla-
ia often undergo both cardiac MRI and EPS.
ost of the tests performed. Individual test costs in the
United States were obtained from Medicare reimbursement
rates (12) to which we added the Outpatient Prospective
Payment System institutional reimbursement rates and the
minimum unadjusted copayment, providing minimal and
maximal total costs (Online Table 3).
As was already explained, cost projections assumed the
following. 1) Annually, 8.5 million athletes would undergo
ECG screening. 2) Every year, 91% would screen negative,
be allowed to compete, and would be rescheduled for
screening the following year. 3) Two percent would be
disqualified after undergoing additional tests. According to
Italian data, the partition of additional tests (for these 2% of
patients) would be as follows: echocardiography for all;
exercise testing for 82%; Holter recordings for 41%; and
MRI, catheterization, and/or EPS in 5% (Online Table 2).
4) Seven percent would undergo secondary testing and
would be allowed to compete, though they would be
rescheduled for intensified follow-up consisting of: echocar-
diography for all; exercise testing for 19%; Holter monitors
for 5%; and MRI, catheterization, and/or EPS in 1%
(Online Table 2). The frequency of secondary testing in the
last subgroup was not stated in the original report by
Corrado et al. (7) and that information was retrieved from
a separate report (by the same investigators) dealing with
athletes who have abnormal ECG but normal echocardio-
gram on initial screening (13). In this population, additional
tests were performed at least twice during follow-up of
almost 10 years (13). Accordingly, we assumed that for the
7% with abnormal ECG who were not disqualified, physical
examination and ECG would be repeated annually, whereas
auxiliary testing would be repeated 4 times during the 20 years
of screening. This too was a conservative assumption because
the present guidelines (14) recommend thorough reevaluation
every 2 years once a cardiomyopathy is suspected.
Number of lives saved credited to screening. The per-
ception that ECG screening saves lives is derived from the
study by Corrado et al. (7) comparing the incidence rates of
SCD among athletes before and after the implementation of
mandatory ECG screening. In that study, the pre-screening
period was 3 years (1979 to 1981), whereas the post-screening period was much longer (1982 to 2004) (Fig. 1A).
During the pre-screening period, the annual death rate
actually increased from 3.6 per 100,000 athlete-years in
1979 and 1980 to 4.0 per 100,000 athlete-years immediately
prior to mandatory screening initiation. During the post-
screening period, the annual death rate decreased gradually,
reaching a nadir of 0.43 per 100,000 athlete-years in 2001 to
2004 after 20 years of screening (Fig. 1A) (7).
As was already explained, without screening, the number
of athletes (starting at 8.5 million) would increase by 2% per
year. In this unscreened athlete population, the SCD rate
would remain constant, at 4.0 per 100,000 athlete-years,
which is the highest mortality value observed in the pre-
screening period in Italy (red line in Fig. 1B). We then
assumed that with screening and a resultant 2% per year
disqualification rate, the number of athletes in consecutive
years would remain constant (at 8.5 million) and the SCD
rate would decrease over the next 20 years from 4 to 0.43 per
100,000 athlete-years. Furthermore, we assumed that the
decrement in mortality rate over time would assume a linear
function during the 20-year screening period (blue line in
Fig. 1B). The difference between the annual mortality rate
with and without screening could thus be calculated for each
of the individual years of the 2-decade screening period
(bidirectional arrows in Fig. 1B) and the total number of
lives saved was the sum of the all these values. The cost per
life saved was the ratio between total screening costs and the
numbers of lives saved.
Results
ECG screening of all young competitive athletes in the
United States. How much will it cost? A 20-year screen-
ing program including all registered high school and college
athletes, beginning in 2013, would include 8.5 million
athletes. During the course of 2 decades of screening, the
number of athletes undergoing yearly screening would
remain at 8.5 million per year because the number of new
athletes would compensate for the 2% per year disqualifi-
cation rate. Thus, 20 years of annual screening would
culminate in 170 million screening processes. The number
of tests (including annual ECG for all athletes and periodic
secondary tests for a finite proportion of athletes) is shown
in Table 1. Based on the number of tests (Table 1) and their
cost (Table 2, Online Table 3), we estimate that a 2-decade
ECG-screening program involving all registered competi-
tive high school and college athletes in the United States
would cost between $51 and $69 billion (approximately $2.5
to $3.4 billion per year).
ECG screening of all young competitive athletes in the
United States. How many lives will be saved? In our
model, the population of screened and unscreened athletes
initially consists of 8.5 million athletes in each group. In the
unscreened group, the athlete population grows by 2% every
year and the annual mortality rate remains constant at 4/per
100,000 athletes. Consequently, the number of fatalities
netic re
*
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the 20th year of follow-up (Table 3, Fig. 1B). In the
screened group, the number of athletes screened yearly
remains constant at 8.5 million (because the natural growth
in athlete population offsets the 2% per year disqualification
rate) and the mortality gradually decreases from 4 per
100,000 on day 0 to 0.43 per 100,000 athletes on the 20th
year of screening. This represents a mean decrement in
mortality of 0.1785 per 100,000 athlete-years. Accordingly,
the number of fatalities decreases from 340 during the first
year to 37 during the 20th year of screening (Table 3, Fig. 1B).
The number of lives saved accredited to screening increases
from 22 per year after 1 year of screening to 469 per year on the
20th year of screening. The total number of lives saved over 20
years of screening is 4,813 lives (Table 3). Based on the
“minimum” and “maximum” prices for the total 20-year screening
(Table 2) and the total number of lives saved (Table 3), the cost
per life saved ranges from $10.6 to $14.4 million.
Discussion
We estimate that a 20-year program of ECG screening of
young competitive athletes in the United States would cost
between $51 and $69 billion and would save 4,813 lives.
Accordingly, the costs-per-lives saved would be $10
million. This cost is significantly higher than previously
reported (15). That study was also modeled on the Corrado
data (7), but it was based on the assumption that a 1-time
Projected Tests (Including ECG and Additional Testing) During YeaAll Competitive High School and College Athletes During the NextTable 1 Projected Tests (Inclu ing ECG nd Additional TestingAll Competitive High School and College Athletes Duri
Tests Performed Over the Next 2 Decades
No Additional Tests
(91% of 170,000,000) 154,700,000
Additional Tests and Disq
(2% of 170,000,000) 3,4
Examination n Examination
History and exam 154,700,000 History and exam (100%)
ECG 154,700,000 ECG (100%)
Echocardiogram 0 Echocardiogram (100%)
Exercise test 0 Exercise test (82%)
Holter 0 Holter (41%)
MRI, catheterization, EPS 0 MRI, catheterization, EPS (5%)
The number and type of tests is derived from Online Table 2.
ECG  electrocardiogram; EPS  electrophysiologic studies; exam  examination; MRI  mag
Projected Costs of Yearly Screening of All Competitive High SchooDuring the Next 2 Decades in the United StatesTable 2 Projected Costs of Yearly Screening of All CompetitiveDuring the Next 2 Decades in the United States
Test Number of Tests





MRI, catheterization, EPS* 199,750
Total
The “minimal” and “maximal” cost is obtained by multiplying the number of tests in each categor
The cost for cardiac MRI, catheterization, and EPS is the sum of the costs of these 3 tests divided by 3
Abbreviations as in Table 1.screening process would result in a mortality reduction
similar to that observed in Italy with 20 years of annual
screening, thereby reducing the true cost of screening and
artificially enhancing cost-effectiveness (15). Importantly,
the ECG manifestations of the main causes of exercise-
related SCD (hypertrophic cardiomyopathy and right ven-
tricular dysplasia) always develop gradually and may there-
fore become evident only during repeated screening.
Cost-effectiveness analyses should ideally be based on
randomized controlled trials, or at the very least, on obser-
vational studies for which consensus exist. Our cost calcu-
lations were based on a single retrospective study from Italy
(7), which has triggered considerable debate (3,16,17). In
particular, the mortality rate reported in Italy for the
pre-screening period (4 per 100,000 athletes) (7) has been
criticized as excessively high in comparison with other
studies (3,16–18). In fact, the low mortality rate credited to
20 years of continuous screening in Italy (0.4 per 100,000
athletes) does not differ substantially from that reported in
other countries were mandatory ECG screening is not
routinely performed (16,18). Conceding that the “true”
mortality rate without ECG screening is not as high as was
reported in Italy by Corrado et al. (7) would diminish the
absolute mortality reduction credited to ECG screening and
would skyrocket cost-per-life-saved estimations. Certainly,
many will argue that before cost-effectiveness analyses are
performed, the “effectiveness” of ECG screening for saving
reening ofades in the United Statesing Yearly Screening of
e Next 2 Decades in the United States
,000  20  170,000,000 Athlete-Years
d
0
Additional Tests and Not Disqualified
(7% of 170,000,000) 11,900,000
n Examination n
00,000 History and exam (100%) 11,900,000
00,000 ECG (100%) 11,900,000
00,000 Echocardiogram to 100% (only every 5 years) 2,975,000
88,000 Exercise test to 19% (only every 5 yrs) 565,250
94,000 Holter to 5% (only every 5 yrs) 148,750
70,000 MRI, catheterization, EPS to 1% (only every 5 yrs) 29,750
sonance imaging.
College AthletesSchool and College Athletes




















(see Methods and note in Online Table 3).
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Italian study (7) used in our calculations is the cause-
de-exist of the ESC paper endorsing mandatory ECG
screening of athletes (5), and our study is intended for those
who believe the findings reported in the Italian study are
correct. In other words, those who claim (based on Italian
data) that ECG screening saves lives should take a good
look at our analysis to realize how much that strategy costs.
Our expenditure estimation ($10 million per life saved),
high as it may be, probably underestimates what mass ECG
screening of athletes would cost in the United States. First,
expensive tests are likely to be used more liberally in the
United States. For example, in a prospective study at the
University of Virginia (19), 15% of all athletes were referred
for echocardiographic examination and 2% underwent car-
diac MRI studies (vs. 9% and 0.2%, respectively, in Italy
[7]). Mass screening in nonuniversity facilities is likely to
result in even higher rates of additional testing. Second,
African American athletes have a higher prevalence of ECG
Calculated Mortality (SCD) Over 20 Years—With and Without ECG Screening—of the EntirePopul tion of Young Athlet s the Unit d States*
Table 3
Calculated Mortality (SCD) Over 20 Years—
With and Without ECG Screening—of the Entire












0 340 340 0
1 347 325 22
2 354 310 44
3 361 294 66
4 368 279 89
5 375 264 111
6 383 249 134
7 391 234 157
8 398 219 180
9 406 203 203
10 414 188 226
11 423 173 250
12 431 158 273
13 440 143 297
14 449 128 321
15 458 112 345
16 467 97 370
17 476 82 394
18 486 67 419
19 495 52 444
20 505 37 469
Total 8,766 3,954 4,813
*Assumptions: 1) Both populations (“unscreened athletes” and “screened athletes”) consist of 8.5
million athletes at the onset of screening. 2) The number of athletes that need to be screened
increases by 2% per year in the “unscreened athletes” group but remains constant (at 8.5 million
per year) in the “screened athletes” group because the expected annual growth offsets the 2% per
year rate of disqualification from sport participation. 3) The annual mortality rate remains constant
at 4 per 100,000 athletes per year in the unscreened group but decreases by 0.1785 per 100,000
athletes every year (from 4 to 0.43 per 100,000 athletes over 20 years of screening) in the
screened athletes group.
ECG  electrocardiogram; SCD  sudden cardiac death.abnormalities requiring additional tests (20), and theseathletes represent a high proportion of athletes in the
United States, but not in Italy.
The price of ECG screening goes beyond monetary
expenses. A 2/thousand suicide rate, reported for disquali-
fied athletes in Italy (21), is higher by several orders of
magnitude than the SCD rate among unscreened athletes
(7). Although these suicide events may not necessarily be
due to disqualification, they must serve as a reminder of the
profound emotional and financial implications expulsion
might have, particularly when resulting from screening that
was enforced rather than solicited. The long-term risk for
asymptomatic disease carriers, identified solely through
mass-screening processes, may not necessarily replicate the
natural history of patients reported in clinical studies; thus,
physicians advocating screening should acknowledge the
potential for overtreatment.
Study limitations. First, data presented reflect “price”
rather than “cost” (22). For example, the $700 price tag for
an echocardiogram is higher than the actual cost of the test.
However, Medicare reimbursement rates are the best ap-
proximation of the anticipated expenditure that would result
from widespread ECG screening. Furthermore, Medicare
prices have been used for cost-effectiveness calculations in
numerous studies (23). Second, costs could be significantly
reduced by reducing the frequency of screening or by using
a more restrictive definition of “abnormal ECG,” which, in
turn, would reduce the number of expensive auxiliary tests,
as recently endorsed by the ESC (24). However, it is
difficult to predict the impact that such changes would have
on mortality. Third, we calculated “cost-per-lives-saved”
rather than “cost-per-life-year-saved.” The cardiomyopa-
thies identified by screening are progressive in nature. Also,
it is unreasonable to expect that all disqualified athletes will
stop exercising completely (3); yet, the degree of sportive
activity that is completely risk-free remains undefined.
Finally, the majority of disqualified athletes would not
qualify for defibrillator implantation if truly asymptomatic.
For all these reasons, athletes disqualified from sport par-
ticipation should not be expected to have a normal life span.
Clinical implications. The staggering costs of widespread
ECG screening of athletes ($5 billion over the next 2
decades, and $10 million per life saved) have profound
implications for society. To put this expenditure into per-
spective, the cost of alternative strategies to reduce SCD
should be considered. For example, the Medical Emergency
Response Plan for Schools is a public initiative to prepare
high schools for life-threatening emergencies occurring
on-campus. An American Heart Association expert panel
estimated that a preventive program consisting of wide-
spread cardiopulmonary resuscitation training, effective
communication systems within campuses, and external au-
tomatic defibrillators operated by lay rescuers would result
in a cost-per-life-saved of $1.5 to $3.3 million (25). Given
the limited resources available to healthcare in the United
States and the limited life-saving potential of ECG screen-
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other preventive measures for cardiac arrest victims.
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